AxoGen (AXGN) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 17.9% year-over-year to $48.6 million, driven by broad-based growth across the nerve repair portfolio and improved sales productivity.

• Net loss narrowed to $1.9 million ($0.04/share) from $4.1 million ($0.10/share) in Q3 2023; adjusted net income reached $3.1 million ($0.07/share).

• Adjusted EBITDA rose to $6.5 million from $2.4 million last year, reflecting operational improvements and commercial execution.

• FDA accepted the BLA for Avance Nerve Graft, with a PDUFA goal date of September 5, 2025, and no advisory committee planned.

• Recent product launches, including Axoguard HA+ Nerve Protector and Avive+ Soft Tissue Matrix, support growth and market expansion.

Financial highlights

• Revenue increased 17.9% year-over-year to $48.6 million, with gross margin at 74.9%, down from 76.8% last year.

• Operating expenses rose 2.9% to $36.8 million; sales and marketing expenses fell 1.3% to $18.9 million.

• Cash, cash equivalents, and investments totaled $30.5 million at quarter-end, up from $27.1 million at June 30, 2024.

• Operating loss improved to $0.3 million from $4.0 million in Q3 2023.

• Working capital increased to $63.2 million with a current ratio of 3.7x.

Outlook and guidance

• Full-year 2024 revenue guidance maintained at $182–186 million, with gross margin expected at the high end of the 74–76% range.

• Expects to be net cash flow positive cumulatively from April 1 through year-end 2024.

• Anticipates BLA approval for Avance Nerve Graft in September 2025.

• Management expects current liquidity and product sales to fund operations for at least the next 12 months.